Sanofi Ends Itepekimab and Balinatunfib Programs
Sanofi discontinued the clinical programs for itepekimab and balinatunfib as part of a wider pipeline prioritization. Itepekimab will stop across COPD and chronic rhinosinusitis after review of two Phase 3 COPD studies and the…
